QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
Log in

OTCMKTS:UCBJFUCB News Headlines

$127.00
0.00 (0.00 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$127.00
Now: $127.00
$127.00
50-Day Range
$114.65
MA: $122.21
$131.00
52-Week Range
$67.39
Now: $127.00
$131.00
VolumeN/A
Average Volume189 shs
Market Capitalization$24.70 billion
P/E Ratio21.82
Dividend YieldN/A
Beta0.52

Headlines

UCB (OTCMKTS UCBJF) News Headlines

Source:
DateHeadline
UCB SA (OTCMKTS:UCBJF) Receives Consensus Recommendation of "Hold" from BrokeragesUCB SA (OTCMKTS:UCBJF) Receives Consensus Recommendation of "Hold" from Brokerages
americanbankingnews.com - August 6 at 5:30 AM
UCB (OTCMKTS:UCBJF) Stock Rating Lowered by Jefferies Financial GroupUCB (OTCMKTS:UCBJF) Stock Rating Lowered by Jefferies Financial Group
www.americanbankingnews.com - July 31 at 1:35 PM
UCB enters into collaboration with Roche to develop antibody treatment for people living with Alzheimers DiseaseUCB enters into collaboration with Roche to develop antibody treatment for people living with Alzheimer's Disease
www.finanznachrichten.de - July 30 at 11:04 PM
UCB (OTCMKTS:UCBJF) Sets New 1-Year High at $131.00UCB (OTCMKTS:UCBJF) Sets New 1-Year High at $131.00
www.americanbankingnews.com - July 30 at 6:08 AM
UCB out-licenses Alzheimers candidate to RocheUCB out-licenses Alzheimer's candidate to Roche
seekingalpha.com - July 29 at 9:51 AM
UCB Half Year Report 2020UCB Half Year Report 2020
finance.yahoo.com - July 27 at 7:43 AM
UCB (OTCMKTS:UCBJF) Hits New 52-Week High at $128.35UCB (OTCMKTS:UCBJF) Hits New 52-Week High at $128.35
www.americanbankingnews.com - July 24 at 7:12 PM
UCB (UCBJF) Set to Announce Quarterly Earnings on MondayUCB (UCBJF) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - July 20 at 1:38 AM
UCB teams up with Ferring Pharma to commercialize prefilled syringe CimziaUCB teams up with Ferring Pharma to commercialize prefilled syringe Cimzia
seekingalpha.com - July 7 at 3:13 PM
UCB and Ferring Pharmaceuticals Announce Co-Promotion of CIMZIA® (certolizumab pegol) for the Treatment of Adults with Moderate to Severe Crohn's DiseaseUCB and Ferring Pharmaceuticals Announce Co-Promotion of CIMZIA® (certolizumab pegol) for the Treatment of Adults with Moderate to Severe Crohn's Disease
finance.yahoo.com - July 7 at 3:13 PM
First Presentations of Bimekizumab Phase 3 Data Demonstrate Superior Skin Clearance Over Placebo and Stelara® at Week 16 in Adults with Moderate-to-Severe Plaque PsoriasisFirst Presentations of Bimekizumab Phase 3 Data Demonstrate Superior Skin Clearance Over Placebo and Stelara® at Week 16 in Adults with Moderate-to-Severe Plaque Psoriasis
finance.yahoo.com - June 12 at 7:54 PM
UCB acquires Engage Therapeutics for as much as $270MUCB acquires Engage Therapeutics for as much as $270M
seekingalpha.com - June 5 at 8:20 AM
Why Dividend Hunters Love UCB SA (EBR:UCB)Why Dividend Hunters Love UCB SA (EBR:UCB)
finance.yahoo.com - May 5 at 1:31 AM
UCB's General Meeting of ShareholdersUCB's General Meeting of Shareholders
finance.yahoo.com - April 10 at 1:43 PM
Here's Why UCB (EBR:UCB) Can Manage Its Debt ResponsiblyHere's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly
finance.yahoo.com - April 7 at 5:11 PM
UCB SA/NV: Convening notice to the general meeting of shareholdersUCB SA/NV: Convening notice to the general meeting of shareholders
www.finanznachrichten.de - March 27 at 9:21 AM
UCB to divest lineup of alprostadil products to Advanz Pharma for $84MUCB to divest lineup of alprostadil products to Advanz Pharma for $84M
seekingalpha.com - March 6 at 8:01 AM
Read This Before You Buy UCB SA (EBR:UCB) Because Of Its P/E RatioRead This Before You Buy UCB SA (EBR:UCB) Because Of Its P/E Ratio
finance.yahoo.com - February 28 at 7:52 AM
UCB SA 2019 Q4 - Results - Earnings Call PresentationUCB SA 2019 Q4 - Results - Earnings Call Presentation
seekingalpha.com - February 20 at 1:08 PM
The UCB (EBR:UCB) Share Price Is Up 27% And Shareholders Are Holding OnThe UCB (EBR:UCB) Share Price Is Up 27% And Shareholders Are Holding On
finance.yahoo.com - January 28 at 8:50 AM
UCB: Osteoporosis Patients Believe Their Condition is Neglected and Deprioritised by Healthcare AuthoritiesUCB: Osteoporosis Patients Believe Their Condition is Neglected and Deprioritised by Healthcare Authorities
finance.yahoo.com - December 12 at 8:52 AM
UCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual MeetingUCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting
finance.yahoo.com - December 9 at 11:51 PM
UCBs bimekizumab tops Humira in late-stage psoriasis studyUCB's bimekizumab tops Humira in late-stage psoriasis study
seekingalpha.com - December 6 at 1:29 PM
Bimekizumab Phase 3 Psoriasis Study Demonstrates Superiority Versus Humira®Bimekizumab Phase 3 Psoriasis Study Demonstrates Superiority Versus Humira®
finance.yahoo.com - December 6 at 7:53 AM
Belgium's UCB says psoriasis drug beats AbbVie's Humira in trialBelgium's UCB says psoriasis drug beats AbbVie's Humira in trial
finance.yahoo.com - December 6 at 7:53 AM
UCB Presents New Data Demonstrating Commitment to Epilepsy at 2019 American Epilepsy Society MeetingUCB Presents New Data Demonstrating Commitment to Epilepsy at 2019 American Epilepsy Society Meeting
finance.yahoo.com - December 5 at 9:14 AM
UCB Announces availability of NAYZILAM® (midazolam) Nasal Spray CIV, the first and only nasal rescue treatment for seizure clusters in the U.S.UCB Announces availability of NAYZILAM® (midazolam) Nasal Spray CIV, the first and only nasal rescue treatment for seizure clusters in the U.S.
finance.yahoo.com - November 25 at 7:16 AM
An Intrinsic Calculation For UCB SA (EBR:UCB) Suggests It's 29% UndervaluedAn Intrinsic Calculation For UCB SA (EBR:UCB) Suggests It's 29% Undervalued
finance.yahoo.com - November 25 at 2:16 AM
UCBs bimekizumab success in second late-stage psoriasis studyUCB's bimekizumab success in second late-stage psoriasis study
seekingalpha.com - November 15 at 10:42 AM
Ra Pharmaceuticals: Undervalued As The Low-Cost Therapy Seeks FDA ApprovalRa Pharmaceuticals: Undervalued As The Low-Cost Therapy Seeks FDA Approval
seekingalpha.com - October 21 at 1:38 PM
How Should Investors React To UCB SA's (EBR:UCB) CEO Pay?How Should Investors React To UCB SA's (EBR:UCB) CEO Pay?
finance.yahoo.com - October 18 at 1:57 AM
UCBs bimekizumab successful in late-stage psoriasis studyUCB's bimekizumab successful in late-stage psoriasis study
seekingalpha.com - October 17 at 7:57 AM
Why Ra Pharmaceuticals Is Skyrocketing TodayWhy Ra Pharmaceuticals Is Skyrocketing Today
www.fool.com - October 12 at 10:38 PM
UCB challenges Roche patent covering IL-17-targeting antibodiesUCB challenges Roche patent covering IL-17-targeting antibodies
seekingalpha.com - October 7 at 2:29 PM
UCB (EBR:UCB) Seems To Use Debt Quite SensiblyUCB (EBR:UCB) Seems To Use Debt Quite Sensibly
finance.yahoo.com - September 26 at 6:30 AM
UCB SA (EBR:UCB) Has Attractive FundamentalsUCB SA (EBR:UCB) Has Attractive Fundamentals
finance.yahoo.com - August 29 at 9:58 PM
The UCB (EBR:UCB) Share Price Is Down 11% So Some Shareholders Are Getting WorriedThe UCB (EBR:UCB) Share Price Is Down 11% So Some Shareholders Are Getting Worried
finance.yahoo.com - August 7 at 4:10 PM
UCB Half Year Report 2019: UCBs Strong Performance Enables Continued Investment Into Future Growth DriversUCB Half Year Report 2019: UCB's Strong Performance Enables Continued Investment Into Future Growth Drivers
finance.yahoo.com - July 25 at 12:52 PM
European advisory group rejects Amgen and UCBs EvenityEuropean advisory group rejects Amgen and UCB's Evenity
seekingalpha.com - June 28 at 10:30 AM
FDA OKs UCBs Cimzia for type of inflammatory arthritisFDA OKs UCB's Cimzia for type of inflammatory arthritis
seekingalpha.com - March 28 at 5:01 PM
Amgen and UCBs Evenity OKd in Japan for osteoporosisAmgen and UCB's Evenity OK'd in Japan for osteoporosis
seekingalpha.com - January 8 at 4:46 PM
This page was last updated on 8/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.